36 min listen
Cyclacel Pharmaceuticals: Interventions for Cell Cycle Abnormalities in Cancer
Cyclacel Pharmaceuticals: Interventions for Cell Cycle Abnormalities in Cancer
ratings:
Length:
39 minutes
Released:
Jan 8, 2023
Format:
Podcast episode
Description
Cyclacel Pharmaceuticals is a clinical-stage, biopharmaceutical company, developing innovative cancer medicines based on cell cycle, transcriptional regulation, and mitosis biology with a focus on oncology and hematology indications. Their lead drug candidate, fadraciclib is a dual CDK2/9 inhibitor currently undergoing investigation of dose escalation in a Phase 1/2 trial.Spiro Rombotis is the founding CEO of Cyclacel. Prior to joining Cyclacel, Spiro served in a number of management positions at public and private biotechs including Centocor, Bristol Myers Squibb, and the Liposome Company. He earned his MBA at Northwestern University’s Kellogg School of Business.In this episode, we discuss cell cycle dysregulation in cancer, precision targeting of proteins in the drug design process, and unique clinical trial design.Hosted by Joe Varriale.
Released:
Jan 8, 2023
Format:
Podcast episode
Titles in the series (84)
Max Tejada - Biologics & Bioassays by Hopkins Biotech Podcast